Literature DB >> 19538965

The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry.

Andrew N Hoofnagle1, Mark H Wener.   

Abstract

Immunoassays have made it possible to measure dozens of individual proteins and other analytes in human samples for help in establishing the diagnosis and prognosis of disease. In too many cases the results of those measurements are misleading and can lead to unnecessary treatment or missed opportunities for therapeutic interventions. These cases stem from problems inherent to immunoassays performed with human samples, which include a lack of concordance across platforms, autoantibodies, anti-reagent antibodies, and the high-dose hook effect. Tandem mass spectrometry may represent a detection method capable of alleviating many of the flaws inherent to immunoassays. We review our understanding of the problems associated with immunoassays on human specimens and describe methodologies using tandem mass spectrometry that could solve some of those problems. We also provide a critical discussion of the potential pitfalls of novel mass spectrometric approaches in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538965      PMCID: PMC2720067          DOI: 10.1016/j.jim.2009.06.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  53 in total

Review 1.  Ion suppression in mass spectrometry.

Authors:  Thomas M Annesley
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

2.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

3.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.

Authors:  John Rush; Albrecht Moritz; Kimberly A Lee; Ailan Guo; Valerie L Goss; Erik J Spek; Hui Zhang; Xiang-Ming Zha; Roberto D Polakiewicz; Michael J Comb
Journal:  Nat Biotechnol       Date:  2004-12-12       Impact factor: 54.908

4.  False-positive serum chromogranin A assay due to heterophile antibody interference.

Authors:  Luca Giovanella; Luca Ceriani; Carmine Lumastro; Antonella Ghelfo
Journal:  Clin Chim Acta       Date:  2006-12-13       Impact factor: 3.786

5.  Efficacy of a new blocker against anti-ruthenium antibody interference in the Elecsys free triiodothyronine assay.

Authors:  Rémy Sapin; Arnaud Agin; Françoise Gasser
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

6.  Anti-thyrotropin antibody interference in thyrotropin assays.

Authors:  R Sapin; M d'Herbomez; J L Schlienger; J L Wemeau
Journal:  Clin Chem       Date:  1998-12       Impact factor: 8.327

7.  Investigation of an albumin-enriched fraction of human serum and its albuminome.

Authors:  Rebekah L Gundry; Qin Fu; Christine A Jelinek; Jennifer E Van Eyk; Robert J Cotter
Journal:  Proteomics Clin Appl       Date:  2007-01-01       Impact factor: 3.494

8.  Electrospray interface for liquid chromatographs and mass spectrometers.

Authors:  C M Whitehouse; R N Dreyer; M Yamashita; J B Fenn
Journal:  Anal Chem       Date:  1985-03       Impact factor: 6.986

9.  LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer.

Authors:  Olga P Bondar; David R Barnidge; Eric W Klee; Brian J Davis; George G Klee
Journal:  Clin Chem       Date:  2007-02-22       Impact factor: 8.327

Review 10.  Mass spectrometry for proteomics.

Authors:  Xuemei Han; Aaron Aslanian; John R Yates
Journal:  Curr Opin Chem Biol       Date:  2008-10       Impact factor: 8.822

View more
  124 in total

1.  Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry.

Authors:  Sean A Agger; Luke C Marney; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2010-10-05       Impact factor: 8.327

2.  Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma.

Authors:  Eric Kuhn; Jeffrey R Whiteaker; D R Mani; Angela M Jackson; Lei Zhao; Matthew E Pope; Derek Smith; Keith D Rivera; N Leigh Anderson; Steven J Skates; Terry W Pearson; Amanda G Paulovich; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2011-12-22       Impact factor: 5.911

Review 3.  Biomedical mass spectrometry in today's and tomorrow's clinical microbiology laboratories.

Authors:  Alex van Belkum; Martin Welker; Marcel Erhard; Sonia Chatellier
Journal:  J Clin Microbiol       Date:  2012-02-22       Impact factor: 5.948

Review 4.  Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions.

Authors:  Paola Picotti; Ruedi Aebersold
Journal:  Nat Methods       Date:  2012-05-30       Impact factor: 28.547

Review 5.  Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS.

Authors:  Jessica O Becker; Andrew N Hoofnagle
Journal:  Bioanalysis       Date:  2012-02       Impact factor: 2.681

6.  Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures.

Authors:  Andrew N Hoofnagle; Jessica O Becker; Michael N Oda; Giorgio Cavigiolio; Philip Mayer; Tomas Vaisar
Journal:  Clin Chem       Date:  2012-02-03       Impact factor: 8.327

7.  Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis.

Authors:  Xiaotao Duan; Lipeng Dai; Shang-Chiung Chen; Joseph P Balthasar; Jun Qu
Journal:  J Chromatogr A       Date:  2012-06-21       Impact factor: 4.759

8.  Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.

Authors:  Vivien Bonert; John Carmichael; Zengru Wu; James Mirocha; Daniel A Perez; Nigel J Clarke; Richard E Reitz; Michael J McPhaul; Adam Mamelak
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

9.  From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry.

Authors:  Russell P Grant; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2014-05-08       Impact factor: 8.327

Review 10.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.